Ignore This Picture
Spacer
faculty photo

Mark T. Osterman, M.D., MSCE

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Attending Physician, Penn Medicine at Radnor, Radnor, PA
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending Physician, Penn Presbyterian Medical Center, Philadelphia, PA
Director, Remicade Infusion Center, Penn Medicine at Radnor, Radnor, PA
Department: Medicine

Contact information
Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 N 39th Street
Philadelphia, PA 19104
Office: 215-662-8900
Fax: 215-662-0950
Education:
BA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Post-Graduate Training
Intern in Internal Medicine, Brigham and Women's Hospital, 1999-2000.
Resident in Internal Medicine, Brigham and Women's Hospital, 2000-2002.
Fellow in Gastroenterology, University of Pennsylvania, 2002-2005.
Fellow in Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2003-2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD. : Comparative effectiveness of infliximab and adalimumab for Crohn’s disease. Clinical Gastroenterology and Hepatology 2014 Notes: in press.

Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Sharfan I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD.: An open label randomized controlled trial of mesalamine dose escalation for ulcerative colitis in remission. Clinical Gastroenterology and Hepatology 2014 Notes: in press.

Osterman MT, Sandborn WJ, Colombel J-F, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar T, Lewis JD. : Increased risk of malignancy with adalimumab combination therapy, compared to monotherapy, in Crohn’s disease. Gastroenterology (146), 941-9, 2014.

Osterman, M.: Mucosal Healing in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 47: 212-21, March 2013.

Kerner C, Lewis JD, Osterman MT: Safety considerations in the medical therapy of ulcerative colitis. Medical Therapy of Ulcerative Colitis. Lichtenstein GR (eds.). Springer Science+Business Media LLC, New York, 2013 Notes: In press.

Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD. : Impact of JC virus antibody testing in patients with Crohn’s disease with loss of response to infliximab: a Markov model. Inflammatory Bowel Diseases 19: 2625-33, 2013.

Scott FI, Osterman MT: Medical treatment of Crohn’s disease. Clinics in Colon and Rectal Surgery 2013 Notes: In press.

Osterman MT. Lichtenstein GR. : Ulcerative colitis. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th Edition. Feldman M, Friedman LS, Brandt LJ (eds.). Saunders Elsevier, Philadelphia, 2013 Notes: In press.

Scott IF, Osterman, MT, Mahoud NN, Lewis JD: Secular Trends in Small-Bowel Obstruction and Adhesiolysis in the United States: 1988-2007. PubMed 204(3): 315-20, September 2012.

Forde KA, Haynes K, Troxel AB, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V: Risk of Myocardial Infarction Associated with Chronic Hepatitis C. virus Infection: A Population-Based Cohort Study. PubMed 19(4)(271-7), April 2012 Notes: In Press.

back to top
Last updated: 04/22/2014
The Trustees of the University of Pennsylvania
 
Spacer

[Return to faculty list]

Spacer
University of Pennsylvania | School of Medicine